Europe Influenza Market size was valued at USD 1.39 billion in 2021 and is expected to reach USD 2.6 billion by 2028, at a CAGR of 9.5% during the forecast period 2022-2028. The European market provides a detailed overview of the Europe Influenza market, and that can be segmented by drug class, by route of administration, and by end user. By drug class, The Europe Influenza market has been segmented into Anti-viral drugs, Interferons, Vaccines. The Platelet – Rich Plasma segment is likely to be the largest and fastest-growing segment in terms of drug class. The supremacy of this segment is owing to the end user of platelet-rich plasma therapy in bone degeneration disease. It was found that platelet-rich plasma therapy for curing knee osteoarthritis has a high success rate and the efficiency depends on the brutality of knee osteoarthritis. However, Cortisone or steroids is projected to grow with the fastest CAGR during the forecast period. It is mainly because corticosteroid injections can cure various spinal conditions and skeletal, and muscular. Dexamethasone, prednisone, methylprednisolone, and hydrocortisone are FDA-approved corticosteroid injections utilized to decrease inflammation and pain. Such characteristics of corticosteroid injections and their need for numerous bone diseases and injuries fuel the growth of the Bone Degeneration Therapeutics Market Share. The inactivated segment is estimated to hold the most dominant share of the global market. The demand for inactivated vaccines in developing and developed countries is due to the increasing focus of industrialists, as these are standardized according to the specific virus strain. This characteristic of the vaccines helps minimize the flu in less time and revert positive effects. The increasing demand, coupled with the high prevalence of influenza, is responsible for the highest CAGR of the segment during the forecast period. Based on the Route of administration, the Europe Influenza market is segmented into Oral, Parenteral Nutrition, and Others. Among these, the Parenteral segment is expected to have a significant growing market during the forecast period 2022-2028. Based on the End user, the Europe Influenza market is segmented Hospital pharmacies and Retail pharmacies, and Others. The Osteoarthritis segment accounts for the largest share in 2021. Hospital & retail pharmacies generated the highest revenue among the distribution channel segment in 2021. This leading position is attributable to the fact that vaccination is generally preferred and conducted at smaller institutions. In addition, the large vaccine supply from hospitals is expected to generate a high market value in the forthcoming years. Therefore, the hospital & retail pharmacies segment is also anticipated to witness the highest CAGR during the forecast period.
In November 2020, European Commission approved Supemtek® which is a quadrivalent recombinant influenza vaccine for the protection against influenza in adults of 18 years and older